Sweden's Genovis Q2 net sales rise 19% on product growth

Genovis AB

23/07/2026 07:12

    

    Overview
  
Sweden-based enzyme tools maker's Q2 net sales rose 19% yr/yr, driven by product growth
Q2 EPS fell yr/yr, impacted by one-off acquisition costs; adjusted EPS was higher
Company completed KPL ApS acquisition, broadening proteomics portfolio and customer base

    

    Outlook
  
Genovis expects increased depreciation and amortization of about SEK 0.7 mln per qtr going forward
Company sees favorable long-term growth prospects following KPL acquisition and portfolio expansion
Genovis is engaged in early-stage discussions for licensing revenue linked to ADC technologies

    

    Result Drivers
  
ACQUISITION IMPACT - Q2 results were affected by transaction costs and strategic expansion following the KPL ApS acquisition
PRODUCT SALES GROWTH - Product sales, excluding services, grew by about 20%, with healthy demand across pharmaceutical and biotechnology customers
GENOMICS PERFORMANCE - Genomics segment delivered its best quarter to date, led by SEQguard sales and broader customer base

    
Company press release: ID:nMFN1rjfLy

    

    Key Details
  

            Metric
          

            Beat/Miss
          

            Actual
          

            Consensus Estimate
          
Q2 Sales
Miss
SEK 34.32 mln
SEK 35.50 mln (2 Analysts)
Q2 EPS
 
SEK 0.02
 
Q2 EBITDA
 
SEK 6.84 mln
 
Q2 Operating Cash Flow
 
SEK 7.91 mln
 

    

    Analyst Coverage
  
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."
Wall Street's median 12-month price target for Genovis AB is SEK30.00, about 54.2% above its July 22 closing price of SEK19.46
The stock recently traded at 34 times the next 12-month earnings vs. a P/E of 33 three months ago

    

    Reuters Recommended Reads
  
July 22 - Switzerland's Lonza H1 sales rise, lifts FY core EBITDA margin forecast
July 23 - France's Sartorius Stedim Biotech H1 revenue rises on recurring consumables
July 21 - Danaher Q2 revenue, adjusted EPS beats on life sciences segment strength; raises outlook

    
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)